Simona Rednic

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

A. J. Tyndall, Bettina Bannert, M.J. Vonk et al. · Annals of the Rheumatic Diseases · 2010 · 1.4K citations

Mapping and predicting mortality from systemic sclerosis

Muriel Elhaï, Christophe Meune, Marouane Boubaya et al. · Annals of the Rheumatic Diseases · 2017 · 642 citations · Full text

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

Yannick Allanore, Christophe Meune, Madelon C Vonk et al. · Annals of the Rheumatic Diseases · 2009 · 261 citations